• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Active Biotech adjusts organization, cuts 47 jobs

Active Biotech adjusts organization, cuts 47 jobs

June 3, 2015
CenterWatch Staff

Active Biotech, a biotechnology company based in Sweden, plans to reduce 47 positions and engage in significant down-sizing of operations due to recent negative trial results.

In April, the results from the phase III trial 10TASQ10 in castration-resistant prostate cancer patients were presented. The results showed that the primary endpoint of delaying disease progression was met. However, tasquinimod did not extend overall survival. These results lead to the discontinuation of the development of tasquinimod and the collaboration agreement with Ipsen. The scientific activities in the preclinical project ISI also will be discontinued and only commercial activities will be performed as of 2016.

Since the majority of Active Biotech employees have been engaged in these projects, the company now has 47 employee redundancies. A notification of planned redundancies has been submitted to the local authorities (Arbetsförmedlingen) for 47 employees out of 56. Active Biotech also has called for negotiations with the trade unions and contacts have been established with organizations such as the Swedish Employment Security Council regarding various support measures for the employees. The planned organizational change is estimated to be fully implemented as of Jan. 1, 2016.

The clinical project laquinimod will be continued according to plan together with the collaboration partner Teva Pharmaceutical Industries. The next important milestone for the laquinimod project is the results from the ongoing phase III study CONCERTO, with the primary endpoint of delaying disability progression in patients with relapsing remitting multiple sclerosis (RRMS). The ANYARA and paquinimod projects remain for out-licensing and RhuDex is developed and fully financed by the partner MediGene.

Active Biotech's planned organizational adjustment leads to substantially reduced operating costs. The operating costs are expected to decrease to approximately $60 million per year, from 2016.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing